Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department is taking steps to make Olaparib available on the NHS for people with prostate cancer.

In October 2022, the National Institute for Health and Care Excellence (NICE) published guidance which does not recommend olaparib for the treatment of prostate cancer. ‘Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer’ is available at the following link:

https://www.nice.org.uk/guidance/ta831

NICE continues to survey new evidence which may affect its published guidance and would consult on proposed changes with a wide range of stakeholders if significant new evidence were to emerge.